NewsRoom Articles - Page 2 of 233

WednesdayApr 15, 2026 9:00 am

Soligenix Inc. (NASDAQ: SNGX) Gains Analytical Validation as Pipeline Progress Drives Forward Outlook

A recent Zacks Small-Cap Research report outlines a number of key milestones that position Soligenix for a potentially eventful period ahead. One of the most notable elements highlighted in the analysis is the strength of the interim data trends observed thus far in the FLASH2 study. Beyond the phase 3 program, the report highlights additional clinical and scientific developments that contribute to the depth of Soligenix’s pipeline. Independent research coverage can play a meaningful role in shaping how emerging biotechnology companies are evaluated, particularly when it brings together clinical progress, financial positioning and forward-looking milestones into a cohesive outlook. A…

TuesdayApr 14, 2026 10:00 am

Preclinical Study Reveals Promising Treatment for Glioblastoma

Glioblastoma is a deadly type of brain cancer which progresses rapidly and kills victims within months. For nearly two decades, no significant progress has been made in developing an effective treatment against this malignancy. Now, a new preclinical study using animal models has unveiled a potential breakthrough that could eliminate these tumors. The study, whose findings were published in the journal Nature, was conducted by scientists at the startup Trogenix. The team is made up of scientists at the Cancer Institute at University College London, the Royal Infirmary at Edinburgh, and the University of Edinburgh. The team developed SSEs technology (Synthetic Super-Enhancers) that entails using a viral vector to carry genetic instructions into glioblastoma tumors. The genetic instructions…

MondayApr 13, 2026 9:45 am

MindBio Therapeutics Corp. (CSE: MBIO) (OTCQB: MBQIF) Offers World’s First Voice-Enabled AI-Powered Drug and Alcohol Platform for Workplace Substance Abuse Screening

Disseminated on behalf of MindBio Therapeutics Corp. (CSE: MBIO) (OTCQB: MBQIF)and may include paid advertising. Workplace substance misuse costs U.S. employers over $81 billion annually through lost productivity, accidents, healthcare costs, and liability, with studies indicating that up to 40% of industrial workplace fatalities involve alcohol misuse. MindBio is introducing the world’s first AI-powered voice analytics system to detect drug and alcohol impairment in real time, initially targeting the South American mining sector, where heavy machinery and remote operations make safety monitoring critical. Such advanced screening technology has relevance to a global market spanning a range of safety-sensitive industries, including…

FridayApr 10, 2026 10:00 am

Immunotherapy Could Be Boosted by Blocking the Removal of Cancer RNA

The immune system is capable of identifying and attacking cancer cells in the body. This process depends on the tumor producing damaged RNA, which then sticks to cell surfaces and provides the antigens that the body identifies as foreign and therefore targets. However, a natural mechanism within the body that removes faulty RNA ironically aids many cancers to avoid detection and therefore limit immune system responses to the disease. Now, a new preclinical study has found that targeting and blocking this clean-up mechanism can allow cancer antigens to express on tumor cells and allow the immune system to quickly identify and attack them. The study was conducted by a University…

FridayApr 10, 2026 9:45 am

LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) Accelerates Cancer Care Innovation with Liora Technologies Acquisition and Leadership Expansion

LIXT is advancing its lead compound LB-100 across different clinical programs aimed at difficult-to-treat cancers The company’s acquisition of Liora Technologies introduces a complementary therapy platform with recurring revenue potential These updates underscore LIXTE’s broader strategy: integrating drug development and med-tech innovation to redefine cancer treatment LIXTE Biotechnology (NASDAQ: LIXT) is executing a differentiated strategy in oncology, extending beyond traditional drug development into a more integrated and multi-dimensional approach to cancer care. With the company’s lead clinical candidate, LB-100, advancing through trials and the addition of Liora Technologies to its platform, they are positioning themselves at the nexus of pharmaceutical…

ThursdayApr 09, 2026 10:30 am

Lixte Biotech Holdings Inc. (NASDAQ: LIXT) Advances Precision Oncology Strategy with LB-100, Expands Clinical and Strategic Partnerships

LIXT is advancing its lead candidate LB-100, a first-in-class therapy designed to enhance the effectiveness of existing cancer treatments The company recently strengthened its position through a strategic partnership with Liora Technologies and the expansion of clinical trials These developments highlight Lixte’s broader mission: To improve cancer outcomes through innovation, combination-based therapeutic strategies Lixte Biotechnology (NASDAQ: LIXT) is emerging as a differentiated player in the oncology ecosystem, advancing a precision-driven approach to cancer treatment which focuses on improving the effectiveness of existing. As a clinical-stage pharmaceutical company, the company is advancing novel compounds built around a unique biological target, with its…

ThursdayApr 09, 2026 10:00 am

Shares of Health Insurers Rally After CMS Bumps Up 2027 Rates

The shares of health insurers in the U.S. recorded gains after the Trump administration announced 2027 payment rate increases for Medicare Advantage that were higher than what had been proposed back in January. That improved rate would increase payments to these firms by about $13bn in the coming fiscal year 2027. In January when the federal government revealed that it would be increasing these payments by 0.09%, the insurance firms took a hit to their stock prices because this rate was much lower than had been expected. Investors viewed that small increase as additional pressure on already tight margins, but the surprise announcement of about 2.8% extra payments to MA firms covering older…

WednesdayApr 08, 2026 9:45 am

From Big Data to Better Drugs: How AI-Driven Platforms Are Changing Cancer Research

Cancer research often relies on massive and complex datasets, which can take time and effort to sift through manually. The proprietary PDAOAI platform from Oncotelic Therapeutics helps with this problem as it was designed to analyze large biomedical datasets to extract meaningful signals and help researchers. The company has also curated a detailed TGF-β literature corpus containing 125,000+ PubMed abstracts that represents all of the scientific knowledge related to TGF-β. This has now expanded to >20M abstracts representing the totality of scientific literature. Cancer research is crucial for understanding, diagnosing, treating, and preventing the disease. However, this research often relies on large…

TuesdayApr 07, 2026 10:00 am

Study Explores Whether a Common Vitamin Could Fight Brain Cancer

Researchers at the University of Calgary in Canada are conducting further trials after early studies revealed that vitamin B3, or niacin, holds promise in restoring immune function in the fight against glioblastoma, a brain cancer that grows aggressively and is hard to treat. For over two decades, no significant advancement has been made to improve treatment outcomes in patients with glioblastoma. Treatments like radiation, surgery and chemotherapy help, but the tumors regrow and survival times are dismal. The team at the University of Calgary wanted to establish whether vitamin B3 in high doses may boost treatment outcomes when used alongside current treatment approaches. The scientists want to find out whether this…

MondayApr 06, 2026 10:00 am

Gallup Poll: Healthcare Returns to the Top of Americans’ Biggest Domestic Worries

According to a poll conducted by Gallup in March, Americans are most concerned about healthcare. This finding is notable given the escalation in the Iran war and the way events in the Middle East are currently dominating news headlines. Gallup conducted a poll seeking the views of Americans about how much they worry about a list of 15 policy areas on the domestic front. 61% of the respondents revealed that they are greatly worried about healthcare. The next four biggest sources of worry for Americans were connected to economic issues. Those policy issues are the state of the economy, concerns about inflation in the country, spending by…

News and publishing service for medical and biotechnology related companies

Contact us: 512.354.7000

Soligenix Inc. (NASDAQ: SNGX) Gains Analytical Validation as Pipeline Progress Drives Forward Outlook

Preclinical Study Reveals Promising Treatment for Glioblastoma

MindBio Therapeutics Corp. (CSE: MBIO) (OTCQB: MBQIF) Offers World’s First Voice-Enabled AI-Powered Drug and Alcohol Platform for Workplace Substance Abuse Screening

Immunotherapy Could Be Boosted by Blocking the Removal of Cancer RNA

LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) Accelerates Cancer Care Innovation with Liora Technologies Acquisition and Leadership Expansion

Lixte Biotech Holdings Inc. (NASDAQ: LIXT) Advances Precision Oncology Strategy with LB-100, Expands Clinical and Strategic Partnerships

Shares of Health Insurers Rally After CMS Bumps Up 2027 Rates

From Big Data to Better Drugs: How AI-Driven Platforms Are Changing Cancer Research

Study Explores Whether a Common Vitamin Could Fight Brain Cancer

Gallup Poll: Healthcare Returns to the Top of Americans’ Biggest Domestic Worries

Official NewsWire Relationships

BioMedWire Currently Accepts

BioMedWire

Company Search

Site Search